Insilico Medicine

Rapid Oral presentation will report initial Phase I data for ISM6331 in patients with advanced solid tumors FDA Fast Track- and Orphan Drug-designated program reflects Insilico’s strategy to advance AI-designed medicines against difficult-to-treat, age-associated diseases CAMBRIDGE, Mass. — September 22, 2026 — Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven

View original ↗

Alex Zhavoronkov, co-CEO of the AI drug discovery startup Insilico Medicine, dresses the same way at all his public engagements: a black padded vest with a small white badge that keeps count of the company’s clinical pipeline. When Fortune sat down with him in Hong Kong in July, he made sure to point out the badge’s latest revision: a small circle beside “Phase 3.” The badge is a provocation as much as a point of pri

View original ↗

AI Models & Platforms Insilico Medicine Releases Open Longevity AI Toolkit in Cell Study Add Unite.AI to your preferred sources on Google Insilico Medicine on September 17, 2026 announced the publication of a study in Cell introducing an openly released AI toolkit for aging biology: the LongevityBench benchmark, a family of five compact Longevity-LLMs, and the Longevity Claw agentic research platform. Publication in

View original ↗

Research published in the Journal of Medicinal Chemistry showcases a novel PROTAC series from Insilico Medicine UAE, advancing local research in targeted protein degradation - Insilico Medicine AI R&D Center in Abu Dhabi adds a new discovery milestone to the company’s UAE operations, with research on BTK degraders for potential applications in blood cancers. - Chemistry42 supported the design of novel molecular build

View original ↗

The paper introduces three interconnected resources for the global scientific community: - LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology; - Longevity-LLMs, a family of compact, open-source language models specifically trained on clinical and multi-omics aging data; and - Longevity Claw, an open-source agentic research platform that auton

View original ↗

The program applies generative AI and programmable RNA medicine to design single-administration, self-limiting in vivo cell therapies that clear the earliest culprit cells of age-related disease. - The new research initiative aims to develop programmable, self-limiting preventive treatment to eliminate early cellular drivers of age-related diseases. - Powered by Pharma.AI and aging foundation models, the approach tar

View original ↗

Insilico Medicine announced the publication of a study in Nature Biotechnology showing that its AI-discovered idiopathic pulmonary fibrosis drug candidate rentosertib produced reductions in predicted biological age across six independently developed proteomic aging clocks. The research analyzed longitudinal serum proteomic data collected during a Phase IIa clinical trial of rentosertib in idiopathic pulmonary fibrosi

View original ↗

CAMBRIDGE, Mass., Sep 10, 2026 — Insilico Medicine (“Insilico,” HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its firs

View original ↗

A joint study by Insilico Medicine, the University of Copenhagen, and academic partners identifies NDRG1 as a key regulator of DNA damage repair, demonstrating that targeting this pathway via the antimalarial drug quinacrine triggers synthetic lethality in specific cancer subtypes. Insilico Medicine (HKEX:3696, "Insilico"), a clinical-stage biotechnology company pioneering generative artificial intelligence (AI) for

View original ↗

Collaborative Study with University of Chicago and Johns Hopkins University Establishes First Multi-Omic Map and Actionable AI Targets for Rare Head and Neck Malignancy CAMBRIDGE, Mass. — Aug 4, 2026 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology. The

View original ↗